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Uncommon mutational profiles 
of metastatic colorectal cancer 
detected during routine genotyping 
using next generation sequencing
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Jessica Demange1, Agnès Leroux2, Jean-Louis Merlin2 & Alexandre Harlé  3,4
RAS genotyping is mandatory to predict anti-EGFR monoclonal antibodies (mAbs) therapy resistance 
and BRAF genotyping is a relevant prognosis marker in patients with metastatic colorectal cancer. 
Although the role of hotspot mutations is well defined, the impact of uncommon mutations is still 
unknown. In this study, we aimed to discuss the potential utility of detecting uncommon RAS and 
BRAF mutation profiles with next-generation sequencing. A total of 779 FFPE samples from patients 
with metastatic colorectal cancer with valid NGS results were screened and 22 uncommon mutational 
profiles of KRAS, NRAS and BRAF genes were selected. In silico prediction of mutation impact was then 
assessed by 2 predictive scores and a structural protein modelling. Three samples carry a single KRAS 
non-hotspot mutation, one a single NRAS non-hotspot mutation, four a single BRAF non-hotspot 
mutation and fourteen carry several mutations. This in silico study shows that some non-hotspot RAS 
mutations seem to behave like hotspot mutations and warrant further examination to assess whether 
they should confer a resistance to anti-EGFR mAbs therapy for patients bearing these non-hotspot 
RAS mutations. For BRAF gene, non-V600E mutations may characterise a novel subtype of mCRC with 
better prognosis, potentially implying a modification of therapeutic strategy.
Combination of targeted therapies like anti-EGFR monoclonal antibodies (anti-EGFR mAbs) with chemother-
apy regimen (FOLFOX or FOLFIRI) improves progression-free (PFS) and overall survival (OS) in patients with 
metastatic colorectal cancer (mCRC)1. Tumor mutation hotspots associated with clinical resistance to anti-EGFR 
mAbs like KRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), exon 4 (codons 117 and 146) and 
NRAS exon 2 (codons 12 and 13), exon 3 (codons 59 and 61) and exon 4 (codons 117 and 146) are now well 
identified and are systematically assessed prior to anti-EGFR mAbs prescription1–5. KRAS and NRAS are both 
Ras serine-threonine kinases, located downstream of EGFR in the Ras/Raf/MAPK pathway. Mutations in these 
codons cause constitutive activation of the RAS-MAPK pathway. KRAS and NRAS mutations are reported in 
40–50% and 5–8% of patients with mCRC, respectively6.
Tumor KRAS and NRAS mutational statuses are usually assessed using polymerase chain reaction 
(PCR)-based assays designed for detection of major hotspot mutations. Most PCR-based assays, by their design, 
are not able to detect non-hotspot mutations; thus, patients with a tumor bearing a non-hotspot mutation are 
labeled as “wild-type” even though a tumor mutation exists. Next generation sequencing (NGS) assays allow the 
analysis of full exons and are able to detect uncommon mutational profiles. The impact of non-hotspot mutations 
of KRAS, NRAS and BRAF on anti-EGFR mAbs resistance is still unclear and it may be useful to study their 
impact in patients with mCRC.
BRAF is a serine-threonine kinase, located downstream of EGFR in the Ras/Raf/MAPK pathway7. BRAF 
mutations are reported in 5–10% of patients with mCRC3,6,8. p.(Val600Glu) (V600E) is the main BRAF hotspot 
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mutation9. This mutation, located on exon 15 of the BRAF protein kinase activation domain leads to an increase 
of BRAF activity, 130 to 700 times higher than in wild-type (WT) BRAF10,11. In mCRC, this hotspot mutation 
is recognized as a poor prognosis factor9. Non-hotspot mutations have also an impact on BRAF protein activity, 
leading to high, intermediate or impaired kinase activity12,13.
The aim of this study was to identify isolated or concomitant non-hotspot RAS and BRAF mutations detected 
during routine sequencing by NGS and discuss their potential role in treatment resistance and prognosis for 
patients with mCRC using in silico prediction tools.
Results
We retrospectively collected data from 857 mCRC samples including 779 samples with valid NGS results. DNA 
quality was suitable for 91% of the samples for NGS and uncommon mutational profiles were reported in 22 (2.7% 
of total) samples.
The histological subtypes were: adenocarcinoma for 11 samples, liberkunhian adenocarcinoma for 9 samples, 
mucinous carcinoma for 1 sample, and ductal carcinoma for 1 sample. Twenty samples were from primary tumors 
and 2 were from liver metastases (Table 1).
The range of coverage for rare KRAS, NRAS or BRAF mutations was 700 to 27 000x. Mutant allele fraction 
was between 1.8% and 40.6% for non-hotspot NRAS mutations, between 4.0% and 14.5% for non-hotspot KRAS 
mutations and between 7.9% and 46.2% for non-hotspot BRAF mutations. Thirty-five mutations were missense 
mutations, 5 were silent mutations and one was a stop mutation.
All observed mutations are described in Table 1. Among 22 samples, 3 carried an isolated non-hotspot KRAS 
mutation (#3, #4, #5), 1 a NRAS mutation (#6) and 4 a BRAF non-hotspot mutation (#13, #14, #15, #21). Seven 
concomitant RAS mutations (#1, #2, #7, #8, #9, #10, #19) and 7 concomitant RAS and BRAF mutations (#11, #12, 
#16, #17, #18, #20, #22) were detected. One sample (#12) bore an HRAS mutation not previously described and 
no sample carried MAP2K1 mutations. Twelve of these mutations are not yet described as somatic nor as single 
nucleotide polymorphism (SNP) in public database.
For each mutation, the PolyPhen-2 score, SIFT score, their interpretation, and protein domain impacted are 
described in Table 2. All KRAS and NRAS mutations observed in this study are located in the catalytic domain. 
The majority of these mutations are localized in the GTP binding site. For the BRAF gene, all mutations described 
in our study are found in the protein kinase domain. Predictions of the impact of each mutation are given in 
Table 2.
Discussion
In this study, we assessed the value of NGS-based testing to identify uncommon KRAS, NRAS and BRAF muta-
tional profiles associated to in silico projection to evaluate their therapeutic and clinical implications in 779 sam-
ples of patients with mCRC. We identified 22 uncommon mutational profiles with a few missense variants that 
have not been previously reported in the literature, to our knowledge. Structural modelling of the observed mis-
sense variants in BRAF, KRAS and NRAS shows that most of the observed mutations can be accommodated in the 
protein structures without clearly adverse impacts on protein stability (Table 2). In a few cases, FoldX predicts the 
observed mutation to be highly destabilizing, primarily due to the introduction of interatomic clashes (e.g. KRAS 
Gly115Glu). While some such mutations may indeed lead to destabilization and inhibition of protein folding, it 
should be noted that the modelling procedure in FoldX does not consider backbone conformational changes. It 
is possible that some such mutations could be accommodated in the protein structure once backbone conforma-
tional changes are considered; an example is the RAS Gln61Leu mutation (not observed in this study)14. Despite 
this limitation, FoldX provides a quick, relatively accurate and parsimonious means to evaluate the impacts of 
mutations on protein stability.
We now briefly describe the results of modelling the previously unreported mutations. Modelling the 
Gly115Glu mutation in KRAS (Fig. 1) suggests that this mutation has an adverse impact on protein stability. The 
three point mutations in KRAS that have not been previously reported (Lys88Asn, Cys118Tyr and Asp132Asn) 
are located on the protein surface and lead to minimal impacts on stability when KRAS is considered in isolation. 
The same is true of the NRAS Asp33Glu mutation, although this is located in the Switch 1 loop and is not directly 
involved in substrate binding. Examination of structures of RAS proteins in complex with RASGAP and SOS 
(PDB identifiers 1WQ1 and 1XD2, respectively) showed that most of these residues in KRAS and NRAS were not 
directly involved in the interaction with RASGAP and SOS. The exception is NRAS Asp33Glu, which may affect 
the interaction with SOS (Fig. 2)15. The BRAF Ser602Phe mutation leads to moderate stabilization relative to WT 
BRAF. This residue is located on the surface of the protein and is not in the BRAF dimer interface.
BRAF non-V600E mutations were detected in 1.43% of patients tested, which is consistent with previous 
published studies16. The predictive value of these mutations in the context of mCRC is indeterminate. However, 
exon 11 codon 469 BRAF mutations are located on the gene region coding for protein kinase function11. For exon 
11 codon 466 mutations, the amino acid change is located within the glycine-rich loop in the kinase domain17. 
For samples #14 and #16, BRAF exon 15 codon 594 mutations are located on the gene region coding for pro-
tein kinase function and lead to impaired kinase activity, potentially conferring a favorable prognosis18,19. BRAF 
p.(Lys601Glu) (sample #21) is described as pathogenic but without published data on response to anti-EGFR 
mAbs therapy.
We now turn our attention to the 14 mutational profiles in our dataset with concomitant RAS and/or BRAF 
mutations. KRAS and BRAF mutations have been frequently described as mutually exclusive in CRC and con-
comitant KRAS and BRAF mutations are rare, occurring in less than 0.001% of cases20. In our study, in 10 samples 
with uncommon BRAF mutations, 6 are concomitant with a RAS mutation, and 1 BRAF hotspot mutation had a 
concomitant RAS mutation. The percentage of concomitant KRAS and BRAF mutations in our dataset is higher 
than previously described21–27. Since these studies only assessed BRAF codon 600 hotspot mutations, we may 
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infer that hotspot KRAS mutations are more frequently associated with rare BRAF mutations than with hotspot 
mutations. This inference agrees with a previous study which found that patients with BRAF non-V600E muta-
tions were more likely to have concomitant RAS mutations than patients with the BRAF V600E mutation16. Due 
to the infrequent observation of this phenomenon, it is actually not clear whether or not these doubly mutated 
#
Primary tumor 
localization
Tumor lesion 
analyzed Histological type Gene Exon
Nucleotidic 
variation
Protein 
variatio COSMIC ID.a Significance Coverage MAF (%)d
#1 Left colon junction Primary
Lieberkuhnian 
adenocarcinoma
KRAS 2 c.34G > A p.(Gly12Ser) COSM517 Missense 2623 32.0
NRAS 3 c.181C > A p.(Gln61Lys) COSM580 Missense 4133 14.4
#2 Sigmoid Colon Primary Mucinous carcinoma
KRAS 2 c.34G > A p.(Gly12Ser) COSM517 Missense 3412 25.4
NRAS 2 c.38G > T p.(Gly13Val) COSM574 Missense 3009 12.3
#3 Right colon Primary Ductal carcinoma KRAS 2 c.37G > T p.(Gly13Cys) COSM527 Missense 2694 57.9
#4 Sigmoid colon Primary Lieberkuhnian adenocarcinoma KRAS 2 c.37G > T p.(Gly13Cys) COSM527 Missense 800 30.6
#5 Colon Metastasis (liver) Lieberkuhnian adenocarcinoma KRAS 2 c.24A > G p.(Val8Val) COSM1360891
Silent 
mutation 1117 70.6
#6 Sigmoid colon Primary Adenocarcinoma NRAS 4 c.360G > A p.(Leu120Leu) Not described* Silent mutation 907 40.6
#7 Right colon Primary Lieberkuhnian adenocarcinoma
KRAS 4 c.360G > A p.(Leu120Leu) Not described* Silent mutation 2688 48.0
KRAS 4 c.353G > A p.(Cys118Tyr) Not described* Missense 2688 14.4
KRAS 4 c.418C > T p.(Pro140Ser) COSM4169136 Missense 2688 6.0
#8 Right colon Primary Adenocarcinoma
KRAS 4 c.344G > A p.(Gly115Glu) Not described* Missense 1634 4.3
NRAS 2 c.69A > G p.(Leu23Leu) rs771113899# Silent mutation 1819 1.8
#9 Sigmoid colon Primary Lieberkuhnian adenocarcinoma
KRAS 3 c.281G > A p.(Arg68Arg) Not described* Silent mutation 1849 25.0
KRAS 4 c.394G > A p.(Asp132Asn) Not described* Missense 1836 4.0
NRAS 2 c.64C > T p.(Gln22)* Not described* Stop mutation 2913 8.0
#10 NA Metastasis (liver) Adenocarcinoma
NRAS 2 c.99T > G p.(Asp33Glu) Not describedb Missense 8161 22.5
KRAS 2 c.35G > T p.(Gly12Val) COSM520c Missense 2397 17.6
#11 Rectum Primary Adenocarcinoma
BRAF 15 c.1742A > G p.(Asn581Ser) COSM462 Missense 4048 27.6
NRAS 2 c.34G > T p.(Gly12Cys) COSM562c Missense 2398 15.7
#12 Right colon Primary Lieberkuhnian adenocarcinoma
KRAS 2 c.40G > A p.(Val14Ile) COSM12722 Missense 2887 14.5
BRAF 15 c.1805C > T p.(Ser602Phe) Not describedb Missense 5208 22.6
HRAS 3 c.217C > T p.(Arg73Cys) Not describedb Missense 2825 19
MET 14 c.3050A > C p.(Glu1017Ala) Not describedb Missense 11344 14.3
#13 Colon Primary Lieberkuhnian adenocarcinoma BRAF 11 c.1396G > A p.(Gly466Arg) COSM253328 Missense 5991 21.2
#14 Colon Primary Adenocarcinoma BRAF 15 c.1781A > G p.(Asp594Gly) COSM467 Missense 11967 31.5
#15 Rectum Primary Lieberkuhnian adenocarcinoma BRAF 11 c.1406G > T p.(Gly469Val) COSM469 Missense 6910 46.2
#16 Duodenum Primary Adenocarcinoma
BRAF 15 c.1780G > A p.(Asp594Asn) COSM27639 Missense 8067 21
KRAS 2 c.38G > A p.(Gly13Asp) COSM532 Missense 3651 19.9
#17 Caecum Primary Lieberkuhnian adenocarcinoma
BRAF 11 c.1406G > C p.(Gly469Ala) COSM460 Missense 5570 31.4
KRAS 2 c.35G > A p.(Gly12Asp) COSM521 Missense 736 50.8
#18 Rectum Primary Adenocarcinoma
BRAF 11 c.1397G > A p.(Gly466Glu) COSM453 Missense 12029 7.9
KRAS 2 c.57G > T p.(Leu19Phe) COSM20818 Missense 12363 6.5
#19 Colon Primary Adenocarcinoma
KRAS 2 c.38G > A p.(Gly13Asp) COSM532 Missense 2083 25.6
KRAS 4 c.436G > A p.(Ala146Thr) COSM19404 Missense 5445 25.6
KRAS 3 c.264A > C p.(Lys88Asn) Not describedb Missense 6549 28.2
#20 Rectum Primary Adenocarcinoma
BRAF 11 c.1406G > C p.(Gly469Ala) COSM460 Missense 20393 31.3
KRAS 4 c.351A > T p.(Lys117Asn) COSM28519 Missense 27295 16.8
#21 Rectosigmoid Primary Adenocarcinoma BRAF 15 c.1801A > G p.(Lys601Glu) COSM478 Missense 9254 23.6
#22 Caecum Primary Adenocarcinoma
BRAF 15 c.1799T > A p.(Val600Glu) COSM476 Missense 12127 32.5
KRAS 2 c.35G > T p.(Gly12Val) COSM520 Missense 9389 49.6
Table 1. Uncommon mutational profiles found in our study and tumor features. aAs described in the Catalogue 
of Somatic Mutations in Cancer (COSMIC), available online at. bNot described as somatic nor as single 
nucleotide polymorphism (SNP) in databases. cKRAS and NRAS hotspot mutation. dMutant allele fraction 
(MAF).
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tumors have a different biology and natural history than KRAS or BRAF mutant tumors. We should illustrate the 
potential significance of this concomitant mutation on sample #12. Sample #12 bears a KRAS p.(Val14Ile) muta-
tion described as pathogenic. Whether resistance to anti-EGFR mAbs is conferred by this mutation is unknown, 
however codon 14 belongs to the same domain as codons 12 and 13. As with mutations on codons 12 and 13, 
this mutation may be associated with a clinical resistance to anti-EGFR antibodies2. In this case, the knowledge 
of this rare mutation may be significant in guiding a therapeutic decision and to explain potential resistance to 
anti-EGFR antibodies. However, the presence of a BRAF non-V600 mutation could modify response to therapy 
and may even lead to potential treatment resistance. Even if first observations show that BRAF plays only a slight 
role in resistance to anti-EGFR mAbs, some BRAF non-hotspot mutations might contribute to reduced efficacy 
of anti-EGFR mAbs18,28.
In silico prediction of the functional effects of the observed mutations using both sequence- and 
structure-based approaches suggests possible biochemical mechanisms related to uncommon mutational profile 
and relevant in cancer. These in silico results warrant further in vivo examination to assess the relevance of detec-
tion of non-hotspot RAS mutations and their implication in resistance to anti-EGFR mAbs therapy. For the BRAF 
gene, non-V600E mutations may describe a novel subtype of mCRC with better prognosis, implying potentially 
different treatment management strategies.
Methods
Samples. Data from 188 formalin-fixed paraffin embedded (FFPE) samples of histologically proven colorec-
tal cancer tumor tissue previously published were pooled with new data from 669 FFPE samples from patients 
with mCRC routinely analyzed for KRAS, NRAS and BRAF mutations from May 2017 to May 2018 in Institut de 
Cancérologie de Lorraine (France)14. All samples were FFPE tissues from mCRC primary tumor or metastases. 
Determination of percentage of tumor tissue content and area for macrodissection were based on examination of 
hematoxylin-eosin stained sections by a senior pathologist. All patients involved in this study gave their informed 
consent for the research of KRAS, NRAS and BRAF mutation. The experimental protocols of these study have 
been approved by the ethical and scientific board of Institut de Cancérologie de Lorraine. All methods were per-
formed in accordance with the relevant guidelines and regulations. All data were anonymized prior to analysis.
DNA extraction and quality assessment. For all samples, DNA was extracted as previously described 
using QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany)14. After extraction of the 669 new samples, 
TruSeq FFPE DNA Library Prep QC kit (Illumina, San Diego, USA) and qPCR using Cobas z480 (Roche 
Diagnostics, Meylan, France) were used for quality DNA assessment. Cycle quantification (Cq) values were cal-
culated using LightCycler® 480 Software W UDF 2.0.0 (Roche Diagnostics). For samples showing a ΔQC score 
lower than 6, DNA libraries were then prepared using TruSeq® Custom Amplicon Library Preparation Kit v1.5 
(Illumina). Fifty-three samples failed to yield sufficient DNA quality and 616 samples qualified for DNA library 
preparation.
DNA library preparation and sequencing. For the first 188 samples, library preparation and DNA 
sequencing were performed using the GS Junior deep pyrosequencing system as previously described14. Library 
preparation was not possible for 11 samples.
For the 616 new samples, libraries were prepared using the TruSeq® Custom Amplicon Library Preparation 
Kit v1.5. This kit consists of two separate oligo pools (CATA and CATB) and allow the full exon analysis of 16 
genes: AKT1 (exon3), ALK (exons 23 to 25), BRAF (exons 11 and 15), EGFR (exons 18 to 21), ERBB2 (exon 20), 
ERBB4 (exons 10 and 12), FGFR2 (exons 7, 12 and 14), FGFR3 (exons 7, 9 and 14), HRAS (exons 2, 3 and 4), KIT 
(exons 8, 9, 11, 13, 17 and 18), KRAS (exons 2, 3 and 4), MAP2K1 (exon2), MET (exons 2 and 14 to 20), NRAS 
(exons 2, 3 and 4), PDGFRA (exons 12, 14 and 18) and PIK3CA (exons 10 and 21). The two oligo pools were 
hybridized to DNA samples. The specific hybridized targets were ligated, extended and PCR amplified with adap-
tors containing index with specific barcode sequences. Two complementary libraries were generated by targeting 
the forward and reverse DNA strands. The PCR-amplified amplicon libraries obtained were then purified using 
AMPure XP beads in order to remove non-specific products and reaction components.
Library DNA concentrations were quantified using Qubit 3.0 Fluorometer (ThermoFisher Scientific Inc, 
Massachusetts, USA) and their quality was assessed on Fragment Analyzer (Advanced Analytical, Ankeny, USA) 
using the Standard Sensitivity NGS Fragment Analysis Kit (Advanced Analytical). PCR product sizes have to be 
around 260 base pairs in length. All 616 validated libraries were normalized to enable similar amplification and 
sequencing levels for each sample library in the same run. Sequencing was performed according to the manufac-
turer’s instructions. All libraries were pooled before sequencing on the MiSeq instrument (Illumina). Sequencing 
data analysis was performed on Sophia DDM® software (Sophia genetics, Saint Sulpice, Switzerland). Reference 
sequences NM_033360.2 for KRAS, NM_002525.4 for NRAS and NM_004333.5 for BRAF were used for align-
ment and variant calling. Fourteen samples had insufficient coverage to be interpretable and 602 samples had 
interpretable sequencing data.
Uncommon mutational profiles. Uncommon mutational profiles were defined as i) a concomitant KRAS 
and NRAS hotspot mutations, or ii) a KRAS, NRAF or BRAF non-hotspot mutation (associated or not associated 
with other mutations). A threshold of 1% allele frequency has been reported clinically relevant for KRAS muta-
tions linked with lack of response to anti-EGFR therapy29.
For samples with an uncommon mutational profile, mutational status of MAP2K1 and HRAS genes (available 
in our gene panel and implicated in the MAPkinase pathway) have been also identified.
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In silico prediction of mutation impact. We used PolyPhen-2 (Polymorphism Phenotyping) and SIFT 
(Sorting Intolerant from Tolerant) scores to predict mutation impact on the protein, as well as FoldX to model the 
observed variants in protein structures30–34. PolyPhen-2 score predicts the possible impact of an amino acid sub-
stitution on the structure and function of a human protein. PolyPhen combines amino acid composition analysis 
in multiple sequence alignments with information from solved protein structures (where available). Sequence 
composition is evaluated using the Position Specific Independent Counts (PSIC) tool, which calculates sequence 
# Gene Exon
Nucleotidic 
variation
Protein 
variation COSMIC ID.a Significance SIFT Score
SIFT score 
interpretation 
Predicted to be
PolyPhen-2 
score
PolyPhen-2 score 
interpretation 
Predicted to be
FoldX ∆∆G 
(kcal/mol)e Protein localization
#1
KRAS 2 c.34G > A p.(Gly12Ser) COSM517 Missense 0.988 Tolerated 0.644 Possibly damaging −0.085 GTP binding site
NRAS 3 c.181C > A p.(Gln61Lys) COSM580 Missense 0.991 Tolerated 0.76 Possibly damaging −0.159 GTP binding site
#2
KRAS 2 c.34G > A p.(Gly12Ser) COSM517 Missense 0.988 Tolerated 0.644 Possibly damaging −0.085 GTP binding site
NRAS 2 c.38G > T p.(Gly13Val) COSM574 Missense 0.975 Tolerated 0.975 Damaging 4.662 GTP binding site
#3 KRAS 2 c.37G > T p.(Gly13Cys) COSM527 Missense 1 Tolerated 0.997 Damaging 2.540 GTP binding site
#4 KRAS 2 c.37G > T p.(Gly13Cys) COSM527 Missense 1 Tolerated 0.997 Damaging 2.540 GTP binding site
#5 KRAS 2 c.24A > G p.(Val8Val) COSM1360891 Silent mutation NA NA NA NA NA Catalytic domain
#6 NRAS 4 c.360G > A p.(Leu120Leu) Not described* Silent mutation NA NA NA NA NA Catalytic domain
#7
KRAS 4 c.360G > A p.(Leu120Leu) Not described* Silent mutation NA NA NA NA NA Catalytic domain
KRAS 4 c.353G > A p.(Cys118Tyr) Not described* Missense 0.988 Tolerated 0.047 Benign 0.516 GTP binding site
KRAS 4 c.418C > T p.(Pro140Ser) COSM4169136 Missense NA NA NA NA 2.970 Catalytic domain
#8
KRAS 4 c.344G > A p.(Gly115Glu) Not described* Missense 1 Tolerated 0.998 Damaging 6.967
GTP binding site
NRAS 2 c.69A > G p.(Leu23Leu) rs771113899# Silent mutation NA NA NA NA NA
#9
KRAS 3 c.281G > A p.(Arg68Arg) Not described* Silent mutation NA NA NA NA NA Catalytic domain
KRAS 4 c.394G > A p.(Asp132Asn) Not described* Missense 0.77 Tolerated 0.004 Benign 0.202 Catalytic domain
NRAS 2 c.64C > T p.(Gln22)* Not described* Stop mutation NA NA NA NA NA Catalytic domain
#10
NRAS 2 c.99T > G p.(Asp33Glu) Not describedb Missense 0.939 Tolerated 0.952 Damaging 0.196 Effector binding site
KRAS 2 c.35G > T p.(Gly12Val) COSM520c Missense 0.993 Tolerated 0.978 Damaging −0.451 GTP binding site
#11
BRAF 15 c.1742A > G p.(Asn581Ser) COSM462 Missense 0.954 Tolerated 0.998 Damaging 0.595 Protein kinase domain
NRAS 2 c.34G > T p.(Gly12Cys) COSM562c Missense 0.935 Tolerated 0.605 Possibly damaging −0.209 GTP binding site
#12
KRAS 2 c.40G > A p.(Val14Ile) COSM12722 Missense 0.999 Tolerated 0.968 Damaging 1.971 GTP binding site
BRAF 15 c.1805C > T p.(Ser602Phe) Not described Missense 0.999 Tolerated 0.916 Damaging −1.341 Protein kinase domain
HRAS 3 c.217C > T p.(Arg73Cys) Not described Missense 1 Tolerated 0.997 Damaging NAf
Catalytic domain
MET 14 c.3050A > C p.(Glu1017Ala) Not described Missense 0.889 Tolerated 0.742 Possibly damaging NA
f
#13 BRAF 11 c.1396G > A p.(Gly466Arg) COSM253328 Missense 1 Tolerated 0.969 Damaging 3.722 ATP binding site
#14 BRAF 15 c.1781A > G p.(Asp594Gly) COSM467 Missense 0.998 Tolerated 0.983 Damaging 1.560 Protein kinase domain
#15 BRAF 11 c.1406G > T p.(Gly469Val) COSM469 Missense 1 Tolerated 0.999 Damaging −3.553 ATP binding site
#16
BRAF 15 c.1780G > A p.(Asp594Asn) COSM27639 Missense 0.999 Tolerated 0.998 Damaging −0.876 Protein kinase domain
KRAS 2 c.38G > A p.(Gly13Asp) COSM532 Missense 0.988 Tolerated 0.506 Possibly damaging 3.455 GTP binding site
#17
BRAF 11 c.1406G > C p.(Gly469Ala) COSM460 Missense 1 Tolerated 0.83 Possibly damagin −1.59 ATP binding site
KRAS 2 c.35G > A p.(Gly12Asp) COSM521 Missense 0.99 Tolerated 0.361 Possibly damaging −0.443 GTP binding site
#18
BRAF 11 c.1397G > A p.(Gly466Glu) COSM453 Missense 1 Tolerated 0.969 Damaging 3.938 ATP binding site
KRAS 2 c.57G > T p.(Leu19Phe) COSM20818 Missense 0.999 Tolerated 0.999 Damaging 5.653 Catalytic domain
#19
KRAS 2 c.38G > A p.(Gly13Asp) COSM532 Missense 0.988 Tolerated 0.506 Possibly damaging 3.455 GTP binding site
KRAS 4 c.436G > A p.(Ala146Thr) COSM19404 Missense 0.993 Tolerated 0.987 Damaging 4.757 GTP binding site
KRAS 3 c.264A > C p.(Lys88Asn) Not describedb Tolerated 0.937 Tolerated 0.094 Benign 0.183 Catalytic domain
#20
BRAF 11 c.1406G > C p.(Gly469Ala) COSM460 Tolerated 1.0 Tolerated 0.835 Possibly damaging −1.595 ATP binding site
KRAS 4 c.351A > T p.(Lys117Asn) COSM28519 Tolerated 0.989 Tolerated 0.998 Damaging 0.317 GTP binding site
#21 BRAF 15 c.1801A > G p.(Lys601Glu) COSM478 Missense 1.0 Tolerated 0.626 Damaging −0.276 Protein kinase domain
#22
BRAF 15 c.1799T > A p.(Val600Glu) COSM476 Missense 0.999 Tolerated 0.943 Damaging 0.930 Protein kinase domain
KRAS 2 c.35G > T p.(Gly12Val) COSM520 Missense 0.993 Tolerated 0.978 Damaging −0.451 GTP binding site
Table 2. SIFT, PolyPhen-2 score and protein localization of each identified mutation. aAs described in the 
Catalogue of Somatic Mutations in Cancer (COSMIC), available online at. bNot described as somatic nor 
as single nucleotide polymorphism (SNP) in databases. cKRAS and NRAS hotspot mutation. dMutant allele 
fraction (MAF). eImpacts of observed mutations on protein stability, as predicted by FoldX. Negative values of 
∆∆G indicate that a mutation stabilizes the protein structure relative to the WT, and positive values indicate 
destabilization. fHRAS and MET mutations were not modelled.
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profiles35. Differences in the profiles calculated by PSIC for the different variants at a site are indicative of damag-
ing impact. In cases where structural data are available, the impact of a mutation is assessed by considering phys-
icochemical properties such as residue size and hydrophobicity, and the maintenance of contacts with ligands, 
metals or other interacting proteins. Sequence- and structure-based features are combined to produce predictions 
using a naïve Bayes classifier. PolyPhen-2 produces scores between 0 and 1 along with annotations of whether the 
mutation is predicted to be benign or damaging.
SIFT also predicts whether an amino acid substitution affects protein function. SIFT scores are used to pre-
dict the damaging effect of nucleotide substitutions and frame shifts (insertions/deletions) on protein function 
Figure 1. Structural model of the KRAS Gly115Glu variant, with key residue sidechains depicted as sticks. The 
Glu residue in position 115 is shown in cyan, along with neighboring residues. For clarity, only residues whose 
atoms contact Glu115 are shown. The mutation to Glu at this position causes severe atomic clashes, primarily 
with residues Ile84 and Arg123, although there is potential for hydrogen bond formation with Arg123. Clashes 
are indicated by colored discs drawn between atoms. The color and size of the disc reflects the severity of the 
clash, with wider, redder discs indicating the most severe clashes.
Figure 2. Close-up view of a section of the interface between Ras (green) and SOS (magenta) at the “catalytic” 
Ras-binding site of SOS26, with Ras residue 33 shown in cyan. Hydrogen bonds are calculated using PyMOL 
and shown as dashed yellow lines. The left panel shows the wild-type Asp33 residue and the right panel shows 
the model of Asp33Glu. The mutation causes a change in the hydrogen bonding pattern at this site. Modelling 
this variant at the “distal” Ras-binding site of SOS shows a similar pattern of change in the hydrogen bonding 
pattern. No significant interatomic clashes are created.
7Scientific RepoRts |          (2019) 9:7083  | https://doi.org/10.1038/s41598-019-43646-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
based on the maintenance of amino acid composition in alignments of the target sequence with closely related 
sequences. The SIFT server assigns scores for each residue from 0 to 1, where mutations with a score of ≤0.05 are 
predicted to not be tolerated, and mutations with score >0.05 are predicted to be tolerated36.
SIFT and PolyPhen-2 scores were determined using Sophia DDM® software (version 5.0.7). Structural mod-
elling of observed missense mutations was carried out using FoldX version 433,34. FoldX estimates the impact of 
point mutations on the folding energy or stability of the protein using rigid-backbone modelling and a classical 
forcefield whose parameters are trained to reproduce experimental observations of mutational impacts on fold-
ing energy. Starting from the wildtype structures for KRAS, BRAF and NRAS (PDB identifiers 4OBE, 5VAM 
and 5UHV, respectively), the missense mutations observed in these proteins were modeled using the FoldX 
BuildModel tool, and the structural and energetic impacts of each mutation were assessed as the predicted change 
in folding energy (∆∆G). Synonymous (silent) and stop mutations were not modeled. All FoldX modelling results 
are available at https://doi.org/10.5281/zenodo.1467311.
Protein domain impacted. KRAS and NRAS protein domains impacted by the different mutations 
described were identified using UCSF Chimera37. The COSMIC database was used to identify protein domains 
impacted by BRAF mutations38.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article. The FoldX 
modelling data that support the findings of this study are available at https://doi.org/10.5281/zenodo.1467311.
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